Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programmeE.H. Baldini, Diana Giannarelli, Enrico Cortesi et al.|Annals of Oncology|2018Cited by 1